Summary of Spyre Therapeutics Conference Call Company Overview - **Company**: Spyre Therapeutics (NasdaqGS:SYRE) - **Focus**: Development of combination therapies for autoimmune diseases, particularly inflammatory bowel disease (IBD) and rheumatology indications [3][4] Key Points and Arguments Industry Positioning - Spyre is well-positioned to capitalize on the emergence of combination therapies in IBD, with TL1A being a potential game-changer in rheumatology [3] - The company is conducting six Phase II readouts in 2026, with significant data catalysts expected [3][6] Product Development - Spyre aims to create best-in-class products across large autoimmune disease markets, focusing on optimized versions of biologics like TL1A and IL-23 [4] - The company is testing these antibodies in two large Phase II studies, initially as monotherapies and then in combinations [4][5] Combination Therapy Strategy - The future of IBD treatment is seen as reliant on effective combinations, with Spyre's portfolio designed to avoid weak components [5] - TL1A has shown potential to outperform existing TNF therapies in IBD, with expectations for additive efficacy when combined with other mechanisms [5][10] Trial Design and Expectations - The SKYLINE study is a platform trial testing six therapies in ulcerative colitis patients, with a seamless transition from open-label to placebo-controlled phases [18][20] - Part A of the trial involves monotherapy cohorts, while Part B will compare monotherapies against combinations and placebo [20][21] Regulatory and Clinical Considerations - The company is focused on minimizing placebo response through careful patient selection and site engagement [35] - Clinically meaningful differences in remission rates are expected to be around 10%, based on historical data from IBD trials [39] Future Directions - Spyre plans to initiate a Phase III program for Crohn's disease following the UC study, leveraging data from both studies for regulatory approval [40][41] - The company is also exploring TL1A's potential in rheumatology, with a focus on advanced therapy-naive and experienced patients [42][48] Commercial Strategy - The recent hiring of a Chief Commercial Officer aims to enhance the understanding of market dynamics, pricing, and reimbursement strategies for upcoming products [55] Additional Important Insights - TL1A's unique mechanism may provide advantages over existing therapies, particularly in terms of safety and convenience [46][47] - The company is targeting a mix of naive and experienced patients in its initial cohorts to broaden the understanding of TL1A's efficacy [48] - The potential market for TL1A in rheumatology is substantial, with cumulative opportunities estimated at nearly $30 billion [46] This summary encapsulates the key points discussed during the Spyre Therapeutics conference call, highlighting the company's strategic focus, product development, trial design, and commercial outlook.

NASDAQ COMMON: XOMA NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES Q1 2026 CORPORATE PRESENTATION XOMA ROYALTY – WHAT WE DO Royalties Milestones Science Structuring DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions w ...

Core Insights - Boston Scientific's Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% from 2026 to 2028, with expectations to exceed 10% average organic revenue growth [1] - The Electrophysiology (EP) business is anticipated to grow approximately 15% over the long-range plan, driven by market share gains and expansion into new areas [1][8] - The WATCHMAN device is the leading percutaneous left atrial appendage closure (LAAC) device globally, with a long-term growth outlook of over 20% contingent on trial outcomes [2][8] - The CRM DX business is expected to grow about 4% over the long-range plan, supported by recent investments and new product launches [3] - The Interventional Cardiology Therapies (ICTx) segment is projected to achieve 10% growth, particularly in emerging markets [4][8] - The Peripheral Interventions, Interventional Oncology, and Embolics businesses collectively represent a $11 billion market, with expected growth around 7% [4] Competitive Landscape - Medtronic's Diabetes business is preparing for an IPO, while its Hugo robotic-assisted surgery system has received FDA approval for urologic procedures [5] - Johnson & Johnson has acquired Halda Therapeutics for $3.05 billion, enhancing its portfolio in prostate cancer therapies [6] Financial Performance - Boston Scientific shares have increased by 7.5% over the past year, outperforming the industry average of 1.7% [7] - The company's forward five-year Price-to-Earnings (P/E) ratio stands at 27.81, above both its median and the industry average [9] Earnings Estimates - Current earnings estimates for Boston Scientific indicate a projected earnings per share of $3.04 for the year ending December 2025, increasing to $3.45 for December 2026 [11]

Core Insights - TREMFYA has shown significant inhibition of radiographic progression in patients with active psoriatic arthritis (PsA) at Week 24, with results sustained through Week 48, indicating its effectiveness in preserving joint health [1][4][5] - More than half of the patients treated with TREMFYA achieved a 50% improvement in signs and symptoms of PsA by Week 48 in the Phase 3b APEX study [1][4] - The study results support Johnson & Johnson's submission of a supplemental Biologics License Application (sBLA) to the FDA for including new evidence in the TREMFYA label regarding the inhibition of structural damage progression in adults with active PsA [6] Efficacy and Safety - At Week 24, TREMFYA demonstrated a 2.5 times greater ability to inhibit joint structural damage compared to placebo, with sustained results through Week 48 [2][3] - Patients in the placebo group who switched to TREMFYA at Week 24 experienced a 57% reduction in the rate of radiographic progression from baseline to Week 48 [3] - The ACR50 response rates, indicating a clinically meaningful improvement, increased from Week 24 to Week 48 in both dosing groups, with nearly half of the patients transitioning from placebo achieving ACR50 by Week 48 [4] Treatment Implications - TREMFYA is positioned as a valuable treatment option for both early intervention and for patients already showing signs of joint damage, as it can inhibit the progression of joint damage [4][5] - It is the first and only fully-human, dual-acting monoclonal antibody approved for treating PsA, targeting IL-23 and binding to CD64, which is significant for immune-mediated diseases [5][11] - The established safety profile of TREMFYA remains consistent, with no new safety signals identified during the study [4][5]

Core Insights - Johnson & Johnson announced new 96-week data demonstrating the durability of TREMFYA (guselkumab) in achieving clinical remission in adults with moderately to severely active Crohn's disease, with rates exceeding 85% in both maintenance dose regimens [1][3][4] Group 1: Clinical Efficacy - At Week 96, clinical remission rates for TREMFYA were reported at 92.0% for the 100 mg every eight weeks regimen and 93.4% for the 200 mg every four weeks regimen [4] - Endoscopic response rates were 65.0% for the 100 mg every eight weeks and 65.1% for the 200 mg every four weeks [4] - Deep remission rates were 38.7% for the 100 mg every eight weeks and 44.1% for the 200 mg every four weeks [4] Group 2: Study Background - The GRAVITI study evaluated TREMFYA subcutaneous induction and maintenance therapy versus placebo, while the GALAXI studies assessed intravenous induction followed by subcutaneous maintenance therapy [5][9] - TREMFYA is the only IL-23 inhibitor to show superior endoscopic outcomes compared to STELARA in a double-blinded registrational program [5] Group 3: Treatment Options - TREMFYA is the first and only approved dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, providing patients with options for both subcutaneous and intravenous induction [2][6] - The treatment offers significant long-term benefits, allowing patients to manage their condition with greater independence [6] Group 4: Safety Profile - Safety data through 96 weeks in the long-term extension periods of the studies were consistent with the established safety profile of TREMFYA [4] - The treatment is approved for adults with moderately to severely active Crohn's disease and ulcerative colitis [6][13]

Core Insights - TREMFYA (guselkumab) has shown clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study for adults with moderately to severely active ulcerative colitis [1][3][4] - TREMFYA is the only IL-23 inhibitor with a fully subcutaneous regimen, following recent FDA approval for subcutaneous induction in adults with ulcerative colitis [1][5] - The study demonstrated robust results across both biologic-naïve and biologic-refractory subgroups, indicating its effectiveness in a diverse patient population [1][4] Study Results - At Week 48, the clinical remission rates were 36.7% for the 100 mg every eight weeks (q8w) regimen and 42.9% for the 200 mg every four weeks (q4w) regimen, compared to 7.2% for placebo [4] - Endoscopic improvement was observed in 44.6% (q8w) and 47.1% (q4w) of patients, while endoscopic remission rates were 25.9% (q8w) and 26.4% (q4w), compared to 5% for placebo [4] - Symptomatic remission rates were 47.5% (q8w) and 53.6% (q4w), against 14.4% for placebo [4] Treatment Flexibility - The subcutaneous induction option allows for at-home administration after proper training, providing flexibility without compromising efficacy [5] - TREMFYA offers a self-administered subcutaneous injection option for starting treatment in ulcerative colitis, maintaining the same efficacy and safety as intravenous induction [5][6] Regulatory Approvals - TREMFYA has received FDA and European Commission approval for both subcutaneous and intravenous induction options for treating adults with moderately to severely active ulcerative colitis and Crohn's disease [6][12] Mechanism of Action - TREMFYA is a dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23, which is implicated in immune-mediated diseases like ulcerative colitis [2][9]

Core Insights - Johnson & Johnson's TREMFYA (guselkumab) has received FDA approval for treating pediatric patients aged six years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, marking it as the first IL-23 inhibitor approved for these indications [1][2][3] Group 1: Approval Details - TREMFYA's approval is based on the PROTOSTAR study, which demonstrated significant skin clearance in pediatric patients at Week 16, with 56% achieving PASI 90 compared to 16% on placebo [4][5] - The treatment is administered via subcutaneous injection at Week 0, Week 4, and then every 8 weeks, with a recommended dosage of 100 mg for pediatric patients [6][8] Group 2: Patient Impact - Approximately 20,000 children under 10 are diagnosed with plaque psoriasis annually, and around 14,000 are affected by psoriatic arthritis, highlighting the need for effective treatment options [2][3] - The approval addresses a significant gap in therapies for pediatric patients suffering from these chronic conditions, which can have long-term physical and emotional impacts [3][7] Group 3: Clinical Study Findings - In the PROTOSTAR study, co-primary endpoints were achieved, with 66% of patients on TREMFYA reaching high levels of skin clearance (IGA score of 0/1) at Week 16 compared to 16% on placebo [4][10] - Safety data indicated that 42% of patients receiving guselkumab reported adverse events, with common issues including nasopharyngitis and upper respiratory infections [10] Group 4: Broader Context - TREMFYA is part of Johnson & Johnson's ongoing commitment to innovate in the treatment of chronic immune-mediated diseases, with previous approvals for adult indications in ulcerative colitis and Crohn's disease [8][24] - The drug's mechanism involves blocking IL-23 and binding to CD64, which is significant in the treatment of immune-mediated diseases [7][15]